Loading…
← CockpitCompetitor Analysis › EUZ.DE Eckert & Ziegler SEOpen in the cockpit ↗

Eckert & Ziegler SEEUZ.DECompetitor analysis, valuation and peers

Germany · EUR·Health Care›Medical Specialties
Momentum leader 81
Mkt cap
$1.03B
US dollars, full cap
Free float
67%
of shares outstanding
$/day
$1.60M
20-day average traded
Fwd P/E
18.5×
forward earnings
ROIC−WACC
+17.2 pp
WACC 10.7%
Hurdle
-4 pp
Req g minus delivered
Next earnings
126 days
24 Mar 2027
Close · EUR€14.98
1D+0.7%
1W+7.5%
1M+16.5%
3M+9.7%
6M-2.3%
YTD-1.8%
1Y-4.4%
ATR %3.1%
52w lowhigh11.1% off high

What Eckert & Ziegler does

Employees: 1,116

Eckert & Ziegler at a glance

Size Eckert & Ziegler (EUZ.DE) is a Germany Health Care company (Medical Specialties) with a market value of $1.03B, the 140th largest of 198 Germany companies the cockpit tracks. Shares closed at €14.98 on 18 Nov 2026.

Performance Over six months the shares fell 2.3%, against -7.9% for the median peer and -0.9% for the Germany market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue grew 4.0% over the last twelve months (peer median +12.3%); the operating margin is 25.7% (peer median 10.3%).

Valuation It trades at 18.5× forward earnings against a peer median of 18.4× (7th cheapest of 13).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 17.2 points above its cost of capital (10.7% WACC).

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026EUZ.DE 95Peer median 92
Six months, rebased to 100: Eckert & Ziegler against the median of its 20 peers (local-currency closes).

Eckert & Ziegler financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€317M€312M€296M€246M€222M
Revenue growth—+5%+20%+11%—
Gross profit€157M€147M€138M€111M€102M
EBITDA€98.6M€92.1M€78.7M€64.5M€57.8M
Net income€54.3M€48.8M€33.3M€26.3M€29.3M
Free cash flow€28.7M€34.4M€50.4M€20.7M€5.92M
Capital expenditure€22.8M€26.0M€17.2M€26.3M€27.1M
Total debt€38.7M€44.8M€55.3M€56.3M€49.6M

Quarterly statements and history in the cockpit →

Eckert & Ziegler competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%CSTL6000553010216523300685IRMD300206SIBNCBLL688622301101300143IART214150ATEC77303046SFLDRTSEUZ.DE6-month return →1-month return →
Up and to the right = strong over both horizons. Eckert & Ziegler is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×6523300685IRMD300206301101300143IART214150ATEC7730SFLEUZ.DERevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Eckert & Ziegler is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%CSTL3010216523300685IRMD300206301101IART21415077303046EUZ.DEGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Eckert & Ziegler is the large dot.

Eckert & Ziegler competitors and peer comparison

How Eckert & Ziegler compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Eckert & Ziegler against its 20 peers (data as of 18 Nov 2026)
MeasureEUZ.DEPeer medianRank in peer set
1-month return+16.5%-5.1%2nd highest of 21
6-month return-2.3%-7.9%8th highest of 20
Distance from 52-week high-11.1%-28.9%3rd highest of 21
Revenue growth (TTM)+4.0%+12.3%6th lowest of 19
Operating margin25.7%10.3%6th highest of 20
Forward P/E18.5×18.4×7th cheapest of 13
Growth the price implies (Req g, 7 yrs)7.7%5.9%6th most demanding of 14
Growth delivered (Del g)+12.1%+10.4%6th highest of 14
Hurdle (Req g minus delivered)-4.4 pp-3.0 pp6th least demanding of 14
ROIC minus cost of capital+17.2 pp+2.9 pp6th highest of 19
EV / EBITDA8.7×9.5×5th cheapest of 10
Net debt / EBITDA-0.8×0.0×4th least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%18.5×7.7%+12.1%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%n/a57.7%+40.6%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%n/an/an/a
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%n/a50.8%+8.6%
PHC 6523.TJapan$1.02B+34%+3%8%7.5×-4.0%+3.5%
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%19.3×4.9%+10.4%
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%
Edan Instruments 300206.SZChina$1.00B-19%+14%17%18.0×6.9%-2.9%
SI-BONE SIBNUnited States$1.06B+59%+14%-8%n/an/an/a
Ceribell CBLLUnited States$995M+42%+31%-70%n/an/an/a
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%n/an/an/a
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%31.6×8.8%+8.8%
INKON Life Technology 300143.SZChina$985M-23%+22%12%50.3×10.7%+12.9%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%6.0×5.9%+3.6%
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%13.7×-9.2%+34.5%
Freenome FRNMUnited States$1.08Bn/an/a36%n/an/an/a
Alphatec ATECUnited States$1.10B-14%+15%-3%15.1×n/an/a
Mani 7730.TJapan$965M-7%+10%30%19.9×3.3%+13.9%
JINS 3046.TJapan$963M-8%+14%10%18.7×-6.1%+11.7%
Safilo SFL.MIItaly$953M+42%-4%9%15.8×1.3%+4.7%
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a

Questions

Which companies are Eckert & Ziegler's closest peers?
The cockpit's peer set: Castle Biosciences (CSTL), Beijing Wandong Medical Technology (600055.SS), Inno Laser Technology (301021.SZ), PHC (6523.T), Amoy Diagnostics (300685.SZ), IRadimed (IRMD), Edan Instruments (300206.SZ), SI-BONE (SIBN).
Is Eckert & Ziegler expensive compared with its peers?
On forward p/e it trades at 18.5× against a peer median of 18.4×, 7th cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has Eckert & Ziegler stock performed?
Over six months to 18 Nov 2026 the shares returned -2.3% against -7.9% for the median peer; over one year -4.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.